Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.

Abstract

OBJECTIVE:

We previously found that Dual-specificity phosphatase 6 (Dusp6) over-expression enhanced the growth-promoting effect of estrogen in endometrial adenocarcinoma cells. The aim of this study was to explore the correlation of Dusp6 expression with progestin sensitivity in atypical endometrial hyperplasia (AEH) and earlier endometrial carcinomas (EC).

METHODS:

Using immunohistochemistry study, we analyzed the expression of Dusp6 protein in AEH.

RESULTS:

We found that progestin treatment was effective in 89% of AEH and 50% of EC. Before treatment, Dusp6 expression was significantly higher in progestin-sensitive AEH groups compared with progestin-resistant groups. After treatment, Dusp6 expression was significantly upregulated in progestin-sensitive groups, but not in progestin-resistant groups. Moreover, a high-dose of Dusp6 transfection significantly enhanced progestin-induced growth-inhibition in Ishikawa cells.

CONCLUSIONS:

Dusp6 could be a predicting marker for deciding the effectiveness of progestin therapy in AEH.

• Authors: Hui Zhang, Lei Yan, Yun Bai, Chunyan Li, Qiufen Guo, Chong Wang, Xingbo Zhao, Mingjiang Li
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 136 Issue 3 Pg. 549-53 (Mar 2015) ISSN: 1095-6859 [Electronic] United States
• PMID: 25451692 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents, Hormonal
• Biomarkers
• Progestins
• Medroxyprogesterone Acetate
• DUSP6 protein, human
• Dual Specificity Phosphatase 6

Topics

• Antineoplastic Agents, Hormonal (therapeutic use)
• Biomarkers (metabolism)
• Cell Line, Tumor
• Drug Resistance, Neoplasm
• Dual Specificity Phosphatase 6 (metabolism)
• Endometrial Hyperplasia (drug therapy, enzymology)
• Endometrial Neoplasms (drug therapy, enzymology)
• Female
• Humans
• Immunohistochemistry
• Medroxyprogesterone Acetate (therapeutic use)
• Precancerous Conditions (drug therapy, enzymology)
• Progestins (therapeutic use)
• Treatment Outcome
• Up-Regulation